

Amendments to the Specification:

Please replace the paragraph beginning at page 7, line 8, with the following amended paragraph:

According to present invention, the pharmaceutical composition contains one or more acrylic acid polymers. In a preferred embodiment of the present invention, the acrylic acid polymer essentially consists of one or a mixture of carbomers. (such as those manufactured by B.F. Goodrich, USA under the trade name 'Carbopol')

Please replace the paragraph beginning at page 8, line 12, with the following amended paragraph:

~~Carbopol~~ Carbomer 971P comprises few cross-link sites which opens up early at low concentration eliminating the interstitial space between the swollen gel particles producing "Fish net" gel structure upon hydration providing significant resistance to small diffusing molecules.

Please replace the paragraph beginning at page 8, line 17, with the following amended paragraph:

~~Carbopol~~ Carbomer 974P on the other hand comprises more cross link sites which does not open up easily producing interstitial space at lower concentration that act as channels for the release of drug at faster rate. This combination of the ~~carbopol~~

carbomer 971P and ~~earbopol~~ carbomer 974P can be manipulated to achieve the desired drug release profile.

Please replace the paragraph beginning at page 8, line 22, with the following amended paragraph:

In accordance with a preferred aspect, in the mix, ~~earbopol~~ carbomer 971P can be at 0.1-20% w/w of the controlled release formulation and ~~earbopol~~ carbomer 974P can be at 0.1-20% w/w of the formulation provided the total ~~earbopol~~ carbomer content is between 0.1-50%.

Please replace the paragraph beginning at page 9, line 21, with the following amended paragraph:

The pharmaceutical composition of the present invention can be prepared by procedures well known to formulation chemists. The method of manufacturing can affect the release characteristics of the composition. The active or their pharmaceutically acceptable hydrates, salts or esters; the hydrophilic polymer of which at least one is ~~earbopol~~ carbomer 971P and other one is ~~earbopol~~ carbomer 974P; one or more water soluble or water dispersible diluents are either mixed together with lubricants and the blend is directly compressed into tablets or are granulated by compaction followed by sieving and the granules obtained are

compressed into tablets.

Please amend the table after the text “Example 1” on page 10 of the specification as follows:

| INGREDIENT | WEIGHT (mg/tab) | % W/W |
|------------------------------------------|--------------------|-------|
| Cefprozil | 53.5 | 66.3 |
| Carbopel <u>Carbomer</u> 971P | 21.2 | 2.7 |
| Carbopel <u>Carbomer</u> 974P | 42.6 | 5.3 |
| PHARMATOSE (lactose) DCL21 | 189.5 | 23.7 |
| Magnesium Stearate | 16.0 | 2.0 |
| Total | 800.0 | 100.0 |

Please amend the table after the text “Example 2,” on page 11 of the specification as follows:

| INGREDIENT | WEIGHT (mg/tab) | % W/W |
|------------------------------------------|--------------------|-------|
| Cefprozil | 530.4 | 66.3 |
| Carbopel <u>Carbomer</u> 971P | 40.0 | 5.0 |
| Carbopel <u>Carbomer</u> 974P | 120.0 | 15.0 |
| PHARMATOSE (lactose) DCL21 | 93.5 | 11.7 |
| Magnesium Stearate | 16.0 | 2.0 |

Applicant: Shailesh Bhamare *et al.*
Application No.: 10/568,325

| | | |
|-------|-------|-------|
| Total | 800.0 | 100.0 |
|-------|-------|-------|

Please amend the table after the text “Example 3,” on page 12 of the specification as follows:

| INGREDIENT | WEIGHT (mg/tab) | % W/W |
|------------------------------------------|--------------------|-------|
| Cefprozil | 530.4 | 66.3 |
| Carbopel <u>Carbomer</u> 971P | 64.0 | 8.0 |
| Carbopel <u>Carbomer</u> 974P | 96.0 | 12.0 |
| PHARMATOSE (lactose) DCL21 | 93.5 | 11.7 |
| Magnesium Stearate | 16.0 | 2.0 |
| Total | 800.0 | 100.0 |

Please amend the table after the text “Example 4,” on page 13 of the specification as follows:

| INGREDIENT | WEIGHT (mg/tab) | % W/W |
|------------------------------------------|--------------------|-------|
| Cefprozil | 530.4 | 66.3 |
| Carbopel <u>Carbomer</u> 971P | 50.0 | 6.2 |
| Carbopel <u>Carbomer</u> 974P | 150.0 | 18.8 |
| PHARMATOSE (lactose) DCL21 | 53.5 | 6.7 |
| Magnesium Stearate | 16.0 | 2.0 |
| Total | 800.0 | 100.0 |

Please amend the table after the text “Example 5,” on page 14 of the specification as follows:

| INGREDIENT | WEIGHT (mg/tab) | % W/W |
|------------------------------------------|----------------------------|--------------|
| Cefadroxil | 531.6 | 66.5 |
| Carbopol <u>Carbomer</u> 971P | 40.0 | 5.0 |
| Carbopol <u>Carbomer</u> 974P | 120.0 | 15.0 |
| PHARMATOSE (lactose) DCL21 | 92.4 | 11.6 |
| Magnesium Stearate | 16.0 | 2.0 |
| Total | 800.0 | 100.0 |

Please amend the table after the text “Example 6,” on page 15 of the specification as follows:

| INGREDIENT | WEIGHT (mg/tab) | % W/W |
|------------------------------------------|------------------------|--------------|
| Cephalexin | 530.2 | 66.3 |
| Carbopol <u>Carbomer</u> 971P | 40.0 | 5.0 |
| Carbopol <u>Carbomer</u> 974P | 120.0 | 15.0 |
| PHARMATOSE (lactose) DCL21 | 93.8 | 11.7 |
| Magnesium Stearate | 16.0 | 2.0 |
| Total | 800.0 | 100.0 |